Altimmune (ALT) Cash from Operations (2010 - 2026)
Altimmune (ALT) reported Cash from Operations of 20942000.0 for Q1 2026, down 24.36% year-over-year from 27685922.44 in Q1 2025, and down 7.68% quarter-over-quarter from 19448000.0 in Q4 2025.
Altimmune (ALT) Cash from Operations (2010 - 2026) Analysis & Trends
Altimmune (ALT) has 17 years of Cash from Operations data on file, last reported at 20942000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 20942000.0, down 24.36% year-over-year; the trailing twelve-month figure through Mar 2026 was 71637000.0 (up 10.82% YoY), and the FY2025 annual result was 67535000.0, up 15.42% from the prior year.
- Cash from Operations declined to 20942000.0 in Q1 2026 per ALT's latest filing, from 19448000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 11897000.0 in Q3 2025 and troughed at 27118000.0 in Q3 2024.
- A 5-year average of 18042411.76 and a median of 18108000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2025: Cash from Operations slumped 43.48% in 2023, then soared 56.13% in 2025.
- A 5-year view of Cash from Operations shows it stood at 17306000.0 in 2022, then gained by 4.47% to 16533000.0 in 2023, then retreated by 10.48% to 18265000.0 in 2024, then retreated by 6.48% to 19448000.0 in 2025, then declined by 7.68% to 20942000.0 in 2026.
- Business Quant data shows ALT's Cash from Operations at 20942000.0 in Q1 2026, 19448000.0 in Q4 2025, and 11897000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Altimmune | 336.67 Mn | 336.67 Mn | - | -20.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.94 Mn |
| Mar 31, 2026 | -20.94 Mn |
| Dec 31, 2025 | -19.45 Mn |
| Dec 31, 2025 | -19.45 Mn |
| Sep 30, 2025 | -11.90 Mn |
| Sep 30, 2025 | -11.90 Mn |
| Jun 30, 2025 | -19.35 Mn |
| Jun 30, 2025 | -19.35 Mn |
| Mar 31, 2025 | -16.84 Mn |
| Mar 31, 2025 | -16.84 Mn |
| Dec 31, 2024 | -18.27 Mn |
| Dec 31, 2024 | -18.27 Mn |
| Sep 30, 2024 | -27.12 Mn |
| Sep 30, 2024 | -27.12 Mn |
| Jun 30, 2024 | -18.11 Mn |
| Jun 30, 2024 | -18.11 Mn |
| Mar 31, 2024 | -16.36 Mn |
| Mar 31, 2024 | -16.36 Mn |
| Dec 31, 2023 | -16.53 Mn |
| Dec 31, 2023 | -16.53 Mn |